Li Xiushen, Liang Weizheng, Yu Chengwei, Meng Qingxue, Zhang Weiwen, Wu Xueliang, Xue Jun, Deng Shoulong, Wang Hao
Department of Obstetrics and Gynecology, Shenzhen University General Hospital, Shenzhen, China.
Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Shenzhen University Health Science Center, Shenzhen, China.
Front Pharmacol. 2022 Sep 29;13:988153. doi: 10.3389/fphar.2022.988153. eCollection 2022.
Patients with colon adenocarcinoma (COAD) are at a higher probability of infection with COVID-19 than healthy individuals. However, there is no globally accepted treatment protocol for patients with COAD/COVID-19. Quercetin has been found to have significant antitumor, antiviral and anti-inflammatory effects in several studies. Therefore, this study sought to evaluate the potential of quercetin as the agent for COAD/COVID-19 and to explore its mechanisms. We used bioinformatics algorithms to obtain COAD/COVID-19-related genes (CCRG) from COAD-related transcriptome data and COVID-related transcriptome sequencing data, and used these genes to construct a COAD prognostic model. We intersected the CCRG with the therapeutic target genes of quercetin and obtained a total of 105 genes (potential target genes of quercetin for the treatment of COAD/COVID-19). By constructing a protein-protein interaction (PPI) network, we ascertained FOS, NFKB1, NFKB1A, JUNB, and JUN as possible core target genes of quercetin for the treatment of COAD/COVID-19. Bioinformatic analysis of these 105 genes revealed that the mechanisms for quercetin the treatment of COAD/COVID-19 may be associated with oxidative stress, apoptosis, anti-inflammatory, immune, anti-viral and multiple pathways containing IL-17, TNF, HIF-1. In this study, we constructed a prognostic model of COAD/COVID19 patients by using CCRG and elucidated for the first time the potential target genes and molecular mechanisms of quercetin for the treatment of COAD/COVID-19, which may benefit the clinical treatment of COAD/COVID-19 patients. However, no clinical trials have yet been conducted to further validate the findings, but this will be the future direction of our research.
结肠腺癌（COAD）患者感染新型冠状病毒肺炎（COVID-19）的概率高于健康个体。然而，目前尚无全球公认的针对COAD/COVID-19患者的治疗方案。多项研究发现，槲皮素具有显著的抗肿瘤、抗病毒和抗炎作用。因此，本研究旨在评估槲皮素作为治疗COAD/COVID-19药物的潜力，并探索其作用机制。我们使用生物信息学算法从COAD相关转录组数据和COVID相关转录组测序数据中获取COAD/COVID-19相关基因（CCRG），并利用这些基因构建COAD预后模型。我们将CCRG与槲皮素的治疗靶点基因进行交集分析，共获得105个基因（槲皮素治疗COAD/COVID-19的潜在靶点基因）。通过构建蛋白质-蛋白质相互作用（PPI）网络，我们确定FOS、NFKB1、NFKB1A、JUNB和JUN为槲皮素治疗COAD/COVID-19可能的核心靶点基因。对这105个基因的生物信息学分析表明，槲皮素治疗COAD/COVID-19的机制可能与氧化应激、细胞凋亡、抗炎、免疫、抗病毒以及包含IL-17、TNF、HIF-1的多种信号通路有关。在本研究中，我们利用CCRG构建了COAD/COVID19患者的预后模型，并首次阐明了槲皮素治疗COAD/COVID-19的潜在靶点基因和分子机制，这可能有助于COAD/COVID-19患者的临床治疗。然而，目前尚未进行临床试验以进一步验证这些发现，但这将是我们未来的研究方向。
